Clifton Life Sciences (CLS) is a leader in the emerging field of molecular diagnostics for both blood and tissue based pathology, developing cell- and tissue-based diagnostic tests for personalized oncological medicine. The company’s products and services are based on its proprietary technology involving the identification of molecular signatures for a variety of neoplastic processes. CLS is developing a novel blood detection system for point-of-care diagnostic applications including melanoma, colon cancer, prostate cancer, multiple myeloma and neuroendocrine tumors as well as other cancers. The CLS platform incorporates a molecular gene cluster signature configuration which produces high performance quantitative laboratory blood test results with the facility of rapid qualitative diagnostic assays.